You are here: Industry Insights > plaque psoriasis

News List

Sun Pharma & Samsung BioLogics announce strategic manufacturing tie-up for Tildrakizumab cphi-online
July 06, 2017
Tildrakizumab is an investigational IL-23p19 inhibitor being evaluated for the treatment of moderate to severe plaque psoriasis.
FDA approves Sun Pharma’s tildrakizumab for moderate-to-severe plaque psoriasis pharmaceutical-technology
May 27, 2017
Indian company Sun Pharmaceutical Industries has received the US Food and Drug Administration (FDA) approval of the Biologics License Application (BLA) for tildrakizumab to treat patients with moderate-to-severe plaque psoriasis.
Almirall and Sun Pharma announce regulatory filing of tildrakizumab in Europe financialexpress
March 27, 2017
Pivotal Phase 3 data demonstrated potential of Tildrakizumab to offer patients treatment for moderate-to-severe plaque psoriasis without burden of frequent injections
Oral OTEZLA demonstrated significant improvement versus Placebo in clinical trial biospectrumasia
March 15, 2017
OTEZLA demonstrated significant improvements versus placebo for the primary and key secondary endpoints at week 16; Safety profile for OTEZLA in UNVEIL was consistent with that of previous trials
New Head-to-Head Data Shows Significantly Higher Response Rates for Lilly's Taltz® (ixekizumab) Comp lilly
March 06, 2017
Eli Lilly and Company announced that patients with moderate-to-severe plaque psoriasis treated with Taltz® (ixekizumab) demonstrated superior efficacy at 24 weeks compared to patients treated with Stelara®* (ustekinumab).
Lilly to Present New Data for Taltz® (ixekizumab) in Psoriasis and Psoriatic Arthritis at the Americ lilly
March 01, 2017
Eli Lilly and Company (NYSE: LLY) will highlight new Phase 3 data evaluating Taltz® (ixekizumab) for the treatment of moderate-to-severe plaque psoriasis and active psoriatic arthritis at the 75th annual meeting of the American Academy of Dermatology (AAD
Siliq (brodalumab) approved by the US FDA for adult patients with moderate-to-severe plaque psoriasi worldpharmanews
February 20, 2017
AstraZeneca's partner Valeant Pharmaceuticals today announced that the US Food and Drug Administration (FDA) has approved Siliq (brodalumab) injection for the treatment of adult patients...
Valeant's treatment for plaque psoriasis gets FDA thumbs up for Siliq cphi-online
February 20, 2017
More than 50% of patients in three clinical studies who used Siliq achieved total skin clearance within a year.
FDA approves Valeant's Siliq for plaque psoriasis firstwordpharma
February 17, 2017
The FDA announced the approval of Valeant Pharmaceuticals' Siliq (brodalumab) to treat adults with moderate-to-severe plaque psoriasis.
FDA Approves Perrigo’s AB Rated Generic Version Of Topicort® Spray, 0.25% americanpharmaceuticalreview
January 25, 2017
Perrigo Company has received U.S. Food and Drug Administration approval for its first-to-file Abbreviated New Drug Application referencing Taro Pharmaceuticals USA Inc.'s Topicort®Spray, 0.25% (desoximetasone topical spray, 0.25%).

Previous page 1 2 3 4 Next page